



07-14-05

IFW

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CERTIFICATE OF MAILING BY EXPRESS MAIL**

**Attorney Docket No. : 202.2D6**

**Applicant(s) : Clarence N. Ahlem, et al.**

**Application Serial No. : 10/741,929**

**For : Pharmaceutical Compositions and Treatment Methods - 6**

**Attorney : Daryl D. Muenchau, Registration No. 36,616**

**Express mail label No. : EV 205130921 US**


**Date of Deposit : July 12, 2005**

I hereby certify that the accompanying:

transmittal form, supplemental information disclosure statement for Serial No. 10/741,929 listing 38 references, copies of 7 references cited in the IDS, return postage prepaid postcard and amendment and response to restriction requirement

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on July 12, 2005 and are addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda Mannon



**PATENT**  
Application S/N 10/741,929  
Docket No. 202.2D6  
Date: July 12, 2005

**MAIL STOP AMENDMENT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450**

---

## **TRANSMITTAL**

Sir:

Transmitted herewith for filing is an information disclosure statement by Applicants.

For: **PHARMACEUTICAL COMPOSITIONS AND TREATMENT METHODS - 6**

Enclosed are:


- (X) Supplemental information disclosure statement 38 references.
- (X) Copies of 7 references (non-U.S. patent or patent publication) cited in the IDS.
- (X) Certificate of mailing by express mail (label No. EV 205130921 US).
- (X) Return postage prepaid postcard.

---

The Commissioner is hereby authorized to charge any fees which may be required, now or in the future, or credit any overpayment to **Deposit Account No. 501536**. Small entity status has previously been claimed for this application.

Please use **Customer No. 26,551** for the correspondence address.


Date: July 12, 2005

  
Daryl D. Muenchau  
Registration No. 36,616  
Attorney of Record  
Hollis-Eden Pharmaceuticals, Inc.  
4435 Eastgate Mall, Suite 400  
San Diego, CA 92121  
Phone: 858-587-9333

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
202.2D6APPLICATION NO.  
10/741,929SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Clarence N. Ahlem, et alFILING DATE  
December 19, 2003GROUP  
1617

(USE SEVERAL SHEETS IF NECESSARY)



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	2,843,608	07-15-58	Colton			
	2	2,843,609	07-15-58	Colton			
	3	4,069,321	01-17-78	Jones et al.			
	4	5,011,678	04-30-91	Wang et al.			
	5	5,116,828	05-26-92	Miura et al.			
	6	5,162,312	11-10-92	Kasch et al.			
	7	5,183,815	02-02-93	Saari et al.			
	8	5,565,444	10-15-96	Mitzushima et al.			
	9	5,795,883	08-18-83	Hesch et al.			
	10	5,817,816	10-06-98	Harimaya et al.			
	11	5,837,700	11-17-98	Labrie			
	12	5,843,934	12-01-98	Simpkins			
	13	5,846,960	12-08-98	Labrie			
	14	5,880,117	03-03-99	Arnold			
	15	6,011,026	01-04-00	Bouali et al.			
	16	6,011,027	01-04-00	Arnold			
	17	6,313,180 B1	11-06-01	Loozen			
	18	6,667,299 B1	12-23-03	Ahlem et al.			

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
202.2D6APPLICATION NO.  
10/741,929SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Clarence N. Ahlem, et alFILING DATE  
December 19, 2003GROUP  
1617

(USE SEVERAL SHEETS IF NECESSARY)

## U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT PUBLICATION NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	19	US 2005/0101581 A1	Ahlem et al.			
	20	US 2005/0026223 A1	Manolagas et al.			
	21	US 2004/0248078 A1	Manolagas et al.			
	22	US 2004/0220114 A1	Ahlem et al.			
	23	US 2004/0224884 A1	Manolagas et al.			
	24	US 2004/0138187 A1	Ahlem et al.			
	25	US 2004/0157812 A1	Labrie			
	26	US 2004/0116359 A1	Ahlem et al.			
	27	US 2004/0097406 A1	Ahlem et al.			
	28	US 2003/0225046 A1	Liao et al.			
	29	US 2003/0083231 A1	Ahlem et al.			
	30	US 2003/0060425 A1	Ahlem et al.			
	31	US 2002/0187970 A1	Labrie			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	32	WO 00/20007	04-13-00	PCT				
	33	WO 99/61044	12-02-99	PCT				
	34	WO 99/63973	12-16-99	PCT				
	35	WO 98/56386	12-17-98	PCT				
	36	WO 93/10141	05-27-93	PCT				

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
202.2D6APPLICATION NO.  
10/741,929SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Clarence N. Ahlem, et alFILING DATE  
December 19, 2003GROUP  
1617EXAMINER  
INITIAL

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE)

- |    |  |
|----|--|
| 37 | Karsenty, The genetic transformation of bone biology, <i>Genes &amp; Development</i> , 13:3037-3051 1999 |
| 38 | Slemenda et al., Sex steroids, bone mass and bone loss, <i>J. Clinical Invest.</i> , 97:14-21 1996       |
|    |  |

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.